# Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

> **NCT01938001** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 358 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Lenalidomide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01938001
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-21
- **Primary completion:** 2018-06-22
- **Final completion:** 2022-01-26
- **Target enrollment:** 358 (ACTUAL)
- **Last updated:** 2023-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01938001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01938001, "Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01938001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*